Jeff Stein, President and CEO, Cidara Therapeutics talks about  their antifungal platform rezafungin now in Phase 3 clinical development to address the needs of the vulnerable population of patients hospitalized for something else who get a life-threatening fungal infection in the hospital. Jeff also explains their Cloudbreak Antiviral Conjugates platform that is being used to target influenza and COVID-19.  Cidara is not developing vaccines or monoclonal antibodies rather long-acting drugs that are virucidal and that recruit the immune system to clean up the infection. He also clearly describes the differences between fungi and viruses.